La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Bank of N.T Butterfield a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Bank of N.T Butterfield..

Bank of N.T Butterfield (NYSE:NTB) Azioni, Catena delle Opzioni

Bank of N.T Butterfield

Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, the Cayman Islands, the Channel Islands, and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.

Bank of N.T. Butterfield & Son Limited (The) Voting Ordinary Shares

Bank of N.T Butterfield & Son Ltd

NOTABLE LABS INC ORD SHS

Notable Labs Ltd

NEW TRIPOLI BANCORP INC by New Tripoli Bancorp, Inc.

New Tripoli Bancorp Inc

NEW TYMBAL RES LTD by NEW TYMBAL RES LTD.

New Tymbal Resources Ltd

BANK NT BUTTERFIELD AND SON ORD

Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) with a Buy and maintains $13 price target.

News

Price Target

Analyst Ratings

PASG

Canaccord Genuity Maintains Buy on Passage Bio, Maintains $13 Price Target

Goldman Sachs analyst Eric Sheridan maintains Chegg (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) with a Neutral and lowers the price target from $3.75 to $1.75.

CHGG

Goldman Sachs Maintains Neutral on Chegg, Lowers Price Target to $1.75

RBC Capital analyst Pammi Bir reiterates Plaza Retail REIT (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PLZ#TSX">PLZ</a>) with a Sector Perform and maintains C$4 price target.

Reiteration

TSX:PLZ

TSX:PLZ/UN

RBC Capital Reiterates Sector Perform on Plaza Retail REIT, Maintains C$4 Price Target

Canaccord Genuity analyst John Newman maintains Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) with a Buy and maintains $10 price target.

MCRB

Canaccord Genuity Maintains Buy on Seres Therapeutics, Maintains $10 Price Target

Goldman Sachs analyst Eric Sheridan downgrades Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Buy to Neutral and lowers the price target from $3.25 to $2.5.

Downgrades

ANGI

Goldman Sachs Downgrades Angi to Neutral, Lowers Price Target to $2.5

Trading Ideas

MTEM

Molecular Templates Shares Resume Trade Following Circuit Breaker Halt

ASML Holding NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) shared its strategic roadmap during the 2024 Investor Day, highlighting key growth drivers and market expectations through <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41962514/asml-provides-updated-view-on-market-opportunities-at-2024-investor-day-meeting" rel="noreferrer noopener">the decade&#8217;s end</a>.
The semiconductor equipment maker projected significant revenue expansion, with scenarios estimating annual sales of $46.51 billion &#8211; $63.43 billion (44 billion euros &#8211; 60 billion euros) by 2030, alongside a gross margin target of 56%-60%.
CEO Christophe Fouquet sees the company&#8217;s extended lithography portfolio and scalable EUV (Extreme Ultraviolet) technology as crucial assets in capturing the potential of these emerging opportunities.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/emerging-markets/24/11/41951575/taiwan-semi-boosts-advanced-chipmaking-with-record-euv-expansion-grabs-56-global-share" rel="noreferrer noopener">Taiwan Semi Boosts Advanced Chipmaking with Record EUV Expansion, Grabs 56% Global Share</a>
ASML expects robust demand from the semiconductor sector, with projected global sales surpassing $1 trillion by 2030.
This outlook translates to an annual market growth rate of around 9% from 2025 to 2030. The firm anticipates a double-digit CAGR for EUV lithography spending within the same period, focusing on advanced Logic and DRAM nodes.
According to ASML, the integration of AI across industries presents a substantial opportunity for semiconductor firms. The company plans to leverage its EUV capabilities to accommodate the rising need for high-performance chips used in AI applications.
The scalability of EUV technology allows for efficient multi-patterning, which ASML expects will drive greater customer adoption through cost-effective manufacturing processes.
ASML&#8217;s CFO, Roger Dassen, highlighted the company&#8217;s confidence in its financial targets, citing a strong pipeline of product demand and increasing lithography spending.
He restated the company&#8217;s capital allocation strategy, which includes substantial returns to shareholders through dividends and share buybacks.
The company is navigating geopolitical tensions between Washington and China as a U.S. ally.
ASML CEO Christophe Fouquet acknowledges <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41876507/asmls-it-outage-affected-chipmaking-operations-worldwide" rel="noreferrer noopener">rising U.S. pressure</a> to restrict chip technology sales to China. Despite this, China remains ASML&#8217;s top market, primarily for sales of mature chips rather than the advanced AI semiconductors targeted by U.S. export restrictions.
ASML dominates the market for specialized lithography machines, essential for companies like Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) in producing cutting-edge chips used in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) smartphones and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) AI processors.
Reports suggest that Taiwan Semiconductor plans to purchase advanced ASML lithography equipment by the end of the year, with each unit priced at $350 million.
Price Actions:&nbsp;ASML stock traded higher by 5.09% at $707.67 at the last check on Thursday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/41977961/mastercards-vision-no-more-passwords-or-card-numbers-by-2030" target="_blank" rel="noreferrer noopener">Mastercard&#8217;s 2030 Vision: A Future Without Passwords, Card Numbers</a></li>
</ul>
Photo via ASML

Tech

AAPL

ASML

NVDA

ASML Projects Revenue Surge to $63 Billion by 2030, Eyes AI and Chip Market Boom

Canaccord Genuity analyst Kyle Mikson maintains Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and maintains $3 price target.

LUCD

Canaccord Genuity Maintains Buy on Lucid Diagnostics, Maintains $3 Price Target

Canaccord Genuity analyst Caitlin Cronin maintains KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) with a Buy and raises the price target from $3 to $4.

KRMD

Canaccord Genuity Maintains Buy on KORU Medical Systems, Raises Price Target to $4

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories A Draw Of 4.407M Barrels Vs A Build Of 1.000M Barrels Est.; Build Of 0.412M Prior

BMO Capital analyst Tamy Chen maintains Martinrea International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MRE#TSX">MRE</a>) with a Outperform and lowers the price target from C$15 to C$13.

TSX:MRE

BMO Capital Maintains Outperform on Martinrea International, Lowers Price Target to C$13

EIA Weekly Distillates Stocks A Draw Of 1.394M Barrels Vs A Build Of 1.000M Barrels Est.; Build Of 2.947M Barrels Prior

Canaccord Genuity analyst Joseph Vafi maintains HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Buy and raises the price target from $6 to $7.

HIVE

Canaccord Genuity Maintains Buy on HIVE Digital Technologies, Raises Price Target to $7

USA Crude Oil Inventories A Build Of 2.089M Barrels Vs A Build Of 0.400M Barrels Est.; Build Of 2.149M Barrels Prior

RBC Capital analyst Greg Pardy maintains Suncor Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SU#TSX">SU</a>) with a Outperform and raises the price target from C$64 to C$66.

TSX:SU

RBC Capital Maintains Outperform on Suncor Energy, Raises Price Target to C$66

BMO Capital analyst Devin Dodge maintains Finning International (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FTT#TSX">FTT</a>) with a Outperform and lowers the price target from C$50 to C$46.

TSX:FTT

BMO Capital Maintains Outperform on Finning International, Lowers Price Target to C$46

Canaccord Genuity analyst George Gianarikas maintains ESS Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWH#NYSE">GWH</a>) with a Hold and maintains $8 price target.

Canaccord Genuity Maintains Hold on ESS Tech, Maintains $8 Price Target

<a href="https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi" title="https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi">https://www.ema.europa.eu/en/medicines/human/EPAR/leqembi</a>

Biotech

Global

General

BIIB

ESAIY

ESALF

CHMP Recommends EU Approval For Eisai's Leqembi To Treat Early Alzheimer's Disease In Apolipoprotein E ε4 Non-Carriers And Heterozygotes; Leqembi, A Monoclonal Antibody, Shown To Slow Cognitive Decline

BMO Capital analyst Etzer Darout maintains Acrivon Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRV#NASDAQ">ACRV</a>) with a Outperform and lowers the price target from $28 to $27.

ACRV

BMO Capital Maintains Outperform on Acrivon Therapeutics, Lowers Price Target to $27

BMO Capital analyst Tamy Chen maintains AutoCanada (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ACQ#TSX">ACQ</a>) with a Market Perform and lowers the price target from C$19.5 to C$19.

TSX:ACQ

BMO Capital Maintains Market Perform on AutoCanada, Lowers Price Target to C$19

Wells Fargo analyst Timur Braziler has maintained their bullish stance on NTB stock, giving a Buy rating on July 24. Timur Braziler has given his B...

Buy Rating Affirmed on Bank of NT Butterfield & Son Amid Strong Capital Returns and Growth Opportunities

Davis International Fund 2024 Semi-Annual Review

Bank of NT Butterfield & Son (NTB) has released an update. Bank of N.T. Butterfield & Son Limited has disclosed its mid-year 2024 capital and risk ...

Bank of Butterfield Mid-Year 2024 Financial Disclosure

Bank of NT Butterfield & Son (NTB) has released an update. The Bank of N.T. Butterfield & Son has announced strategic senior management changes, wi...

Butterfield Bank Strengthens Executive Team

KBW reshuffles rating recommendations on eight regional banks

The Bank of N.T. Butterfield & Son Non-GAAP EPS of $1.16 beats by $0.04, revenue of $142.7M beats by $0.63M

Reports Q3 revenue $142.7M, consensus $142.47M. Michael Collins, Chairman and Chief Executive Officer, commented, "Butterfield delivered strong res...

N.T. Butterfield reports Q3 core EPS $1.16, consensus $1.14

Bank of NT Butterfield & Son (NTB) has released an update. The Bank of N.T. Butterfield & Son has reported a net income of $52.7 million for the th...

Butterfield Reports Strong Q3 2024 Financial Results

The Bank of N.T. Butterfield & Son Limited 2024 Q3 - Results - Earnings Call Presentation

Wells Fargo analyst Timur Braziler maintained a Buy rating on Bank of NT Butterfield & Son (NTB – Research Report) yesterday and set a price target...

Comments

Bank of N.T Butterfield

Bank of N.T Butterfield (NTB) Opzioni

Bank of N.T Butterfield (NYSE:NTB) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO